FGFR2 and gastric cancer: We previously reported that FGFR2 amplification was observed in 4.1% of gastric cancers and that FGFR2 amplification confers hypersensitivity to FGFR inhibitor in gastric cancer cell lines both in vitro and in vivo(15,16), strongly suggesting that FGFR2 amplification may be a promising molecular target for gastric cancer treatment.